## Alisa B Busch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3271209/publications.pdf

Version: 2024-02-01

304743 315739 1,766 76 22 38 citations h-index g-index papers 77 77 77 1812 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Association Between Telepsychiatry Capability and Treatment of Patients With Mental Illness in the Emergency Department. Psychiatric Services, 2022, 73, 403-410.	2.0	3
2	Increases in Inpatient Psychiatry Beds Operated by Systems, For-Profits, and Chains, 2010–2016. Psychiatric Services, 2022, 73, 561-564.	2.0	5
3	Effects of High-Deductible Health Plans on Enrollees With Mental Health Conditions With and Without Substance Use Disorders. Psychiatric Services, 2022, 73, 518-525.	2.0	9
4	Initiating Opioid Use Disorder Medication via Telemedicine During COVID-19: Implications for Proposed Reforms to the Ryan Haight Act. Journal of General Internal Medicine, 2022, 37, 162-167.	2.6	19
5	Disruptions in Care for Medicare Beneficiaries With Severe Mental Illness During the COVID-19 Pandemic. JAMA Network Open, 2022, 5, e2145677.	5.9	31
6	Use of Telemedicine for Buprenorphine Inductions in Patients With Commercial Insurance or Medicare Advantage. JAMA Network Open, 2022, 5, e2142531.	5.9	21
7	Appropriateness of Telemedicine Versus In-Person Care: A Qualitative Exploration of Psychiatrists' Decision Making. Psychiatric Services, 2022, 73, 849-855.	2.0	4
8	High-Deductible Health Plans Paired With Health Savings Accounts Increased Medication Cost Burden Among Individuals With Bipolar Disorder. Journal of Clinical Psychiatry, 2022, 83, .	2.2	0
9	A methodology for identifying behavioral health advanced practice registered nurses in administrative claims. Health Services Research, 2022, 57, 973-978.	2.0	4
10	Psychotropic and pain medication use in nursing homes and assisted living facilities during COVIDâ€19. Journal of the American Geriatrics Society, 2022, 70, 1345-1348.	2.6	6
11	Patient and Clinician Characteristics Associated with Use of Telemedicine for Buprenorphine Induction Among Medicare Beneficiaries. Journal of General Internal Medicine, 2022, 37, 3758-3761.	2.6	8
12	Association Between Telemedicine Use in Nonmetropolitan Counties and Quality of Care Received by Medicare Beneficiaries With Serious Mental Illness. JAMA Network Open, 2022, 5, e2218730.	5.9	4
13	Experiences of health care costs among people with employer-sponsored insurance and bipolar disorder. Journal of Affective Disorders, 2021, 281, 41-50.	4.1	7
14	Behavioral health home impact on transitional care and readmissions among adults with serious mental illness. Health Services Research, 2021, 56, 432-439.	2.0	1
15	Telemedicine for treating mental health and substance use disorders: reflections since the pandemic. Neuropsychopharmacology, 2021, 46, 1068-1070.	5.4	39
16	Clinicians' Perceptions of Rapid Scale-up of Telehealth Services in Outpatient Mental Health Treatment. Telemedicine Journal and E-Health, 2021, 27, 1399-1408.	2.8	36
17	Integrating Stakeholder Engagement With Claims-Based Research on Health Insurance Design and Bipolar Disorder. Psychiatric Services, 2021, 72, 186-194.	2.0	4
18	Use of Electronic Health Information Technology in a National Sample of Hospitals That Provide Specialty Substance Use Care. Psychiatric Services, 2021, 72, 1370-1376.	2.0	4

#	Article	IF	Citations
19	Patterns of Mental Health Care Before Initiation of Telemental Health Services. Medical Care, 2021, 59, 572-578.	2.4	4
20	Association Between Enrollment in Maryland's Behavioral Health Homes and Use of Outpatient Mental Health Services. Psychiatric Services, 2021, 72, 1337-1340.	2.0	1
21	Impact of High Deductible Health Plans on Continuous Buprenorphine Treatment for Opioid Use Disorder. Journal of General Internal Medicine, 2021, , 1.	2.6	8
22	Patients' perceptions of telehealth services for outpatient treatment of substance use disorders during the COVIDâ€19 pandemic. American Journal on Addictions, 2021, 30, 445-452.	1.4	36
23	Impact of High-Deductible Health Plans on Medication Use Among Individuals With Bipolar Disorder. Psychiatric Services, 2021, 72, 926-934.	2.0	1
24	Use of telemedicine for opioid use disorder treatment – Perceptions and experiences of opioid use disorder clinicians. Drug and Alcohol Dependence, 2021, 228, 108999.	3.2	21
25	Is it feasible to pay specialty substance use disorder treatment programs based on patient outcomes?. Drug and Alcohol Dependence, 2020, 206, 107735.	3.2	5
26	The Effect of Centers for Medicare and Medicaid's Inpatient Psychiatric Facility Quality Reporting Program on the Use of Restraint and Seclusion. Medical Care, 2020, 58, 889-894.	2.4	5
27	Telemental Health and US Rural–Urban Differences in Specialty Mental Health Use, 2010–2017. American Journal of Public Health, 2020, 110, 1308-1314.	2.7	44
28	Association of Alternative Payment and Delivery Models With Outcomes for Mental Health and Substance Use Disorders. JAMA Network Open, 2020, 3, e207401.	5.9	23
29	Disparities in outpatient visits for mental health and/or substance use disorders during the COVID surge and partial reopening in Massachusetts. General Hospital Psychiatry, 2020, 67, 100-106.	2.4	67
30	Medication Utilization for Alcohol Use Disorder in a Commercially Insured Population. Journal of General Internal Medicine, 2020, 35, 3262-3270.	2.6	7
31	Adoption of telemedicine services by substance abuse treatment facilities in the U.S Journal of Substance Abuse Treatment, 2020, 117, 108060.	2.8	21
32	Use of Tele–Mental Health in Conjunction With In-Person Care: A Qualitative Exploration of Implementation Models. Psychiatric Services, 2020, 71, 419-426.	2.0	19
33	Treatment of Opioid Use Disorder Among Commercially Insured Patients in the Context of the COVID-19 Pandemic. JAMA - Journal of the American Medical Association, 2020, 324, 2440.	7.4	64
34	Outpatient care for opioid use disorder among the commercially insured: Use of medication and psychosocial treatment. Journal of Substance Abuse Treatment, 2020, 115, 108040.	2.8	8
35	Association Between Broadband Internet Availability and Telemedicine Use. JAMA Internal Medicine, 2019, 179, 1580.	5.1	71
36	Association of Characteristics of Psychiatrists With Use of Telemental Health Visits in the Medicare Population. JAMA Psychiatry, 2019, 76, 654.	11.0	20

3

#	Article	IF	Citations
37	Residential eating disorder outcomes associated with screening positive for substance use disorder and borderline personality disorder. International Journal of Eating Disorders, 2019, 52, 309-313.	4.0	11
38	Acute Phase Treatment Outcomes of Electroconvulsive Therapy in Adolescents and Young Adults. Journal of ECT, 2019, 35, 178-183.	0.6	10
39	Association of Federal Mental Health Parity Legislation With Health Care Use and Spending Among High Utilizers of Services. Medical Care, 2019, 57, 245-255.	2.4	2
40	Coverage of Medications That Treat Opioid Use Disorder and Opioids for Pain Management in Marketplace Plans, 2017. Medical Care, 2018, 56, 505-509.	2.4	27
41	Improving Adoption of EHRs in Psychiatric Care. New England Journal of Medicine, 2018, 378, 1665-1667.	27.0	26
42	Participation in Accountable Care Organizations Among Hospitals Offering Substance Use Disorder and Mental Health Services. Psychiatric Services, 2018, 69, 1131-1134.	2.0	6
43	How Is Telemedicine Being Used In Opioid And Other Substance Use Disorder Treatment?. Health Affairs, 2018, 37, 1940-1947.	5.2	124
44	Federal Parity and Spending for Mental Illness. Pediatrics, 2018, 142, .	2.1	15
45	Medicare Accountable Care Organizations and Antidepressant Use by Patients With Depression. Psychiatric Services, 2017, 68, 1193-1196.	2.0	11
46	Accuracy of Prospective Predictions of 30-Day Hospital Readmission. Psychiatric Services, 2016, 67, 244-247.	2.0	6
47	Utilization of Telemedicine Among Rural Medicare Beneficiaries. JAMA - Journal of the American Medical Association, 2016, 315, 2015.	7.4	141
48	Developing and Implementing an Electronic Patient-Reported Outcomes Measurement Using REDCap in Usual Care Psychiatric Settings. Iproceedings, 2016, 2, e45.	0.1	1
49	Predicting Participation in Psychiatric Randomized Controlled Trials: Insights From the STEP-BD. Psychiatric Services, 2015, 66, 817-823.	2.0	4
50	Improving the efficiency of drug use disorder screening in psychiatric settings: validation of a single-item screen. American Journal of Drug and Alcohol Abuse, 2015, 41, 173-176.	2.1	12
51	Thirty-Day Hospital Readmission for Medicaid Enrollees with Schizophrenia: The Role of Local Health Care Systems. Journal of Mental Health Policy and Economics, 2015, 18, 115-24.	0.6	7
52	Effects of Medicare Part D on Guideline-Concordant Pharmacotherapy for Bipolar I Disorder Among Dual Beneficiaries. Psychiatric Services, 2014, 65, 323-329.	2.0	8
53	Co-occurring depressive and substance use disorders in adolescents: An examination of reward responsiveness during treatment Journal of Psychotherapy Integration, 2014, 24, 109-121.	1.1	23
54	The Effects of Mental Health Parity on Spending and Utilization for Bipolar, Major Depression, and Adjustment Disorders. American Journal of Psychiatry, 2013, 170, 180-187.	7.2	34

#	Article	IF	CITATIONS
55	Racial-Ethnic Differences in Incident Olanzapine Use After an FDA Advisory for Patients With Schizophrenia. Psychiatric Services, 2013, 64, 83-87.	2.0	5
56	Accurately Predicting Bipolar Disorder Mood Outcomes. Medical Care, 2012, 50, 311-319.	2.4	7
57	Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory. Pharmacoepidemiology and Drug Safety, 2012, 21, 1251-1260.	1.9	8
58	Ten-Year Trends in Quality of Care and Spending for Depression. Archives of General Psychiatry, 2011, 68, 1218.	12.3	33
59	Using Multiple Control Groups and Matching to Address Unobserved Biases in Comparative Effectiveness Research. Statistics in Biosciences, 2011, 3, 63-78.	1.2	10
60	New Jersey's Efforts To Improve Postpartum Depression Care Did Not Change Treatment Patterns For Women On Medicaid. Health Affairs, 2011, 30, 293-301.	5.2	60
61	The Rise and Fall of Gabapentin for Bipolar Disorder. Medical Care, 2010, 48, 372-379.	2.4	28
62	Changes in Guideline-Recommended Medication Possession After Implementing Kendra's Law in New York. Psychiatric Services, 2010, 61, 1000-1005.	2.0	11
63	Longitudinal Racial/Ethnic Disparities in Antimanic Medication Use in Bipolar-I Disorder. Medical Care, 2009, 47, 1217-1228.	2.4	17
64	Changes Over Time and Disparities in Schizophrenia Treatment Quality. Medical Care, 2009, 47, 199-207.	2.4	42
65	Bipolar-I patient characteristics associated with differences in antimanic medication prescribing. Psychopharmacology Bulletin, 2009, 42, 35-49.	0.0	6
66	Bipolar-I depression outpatient treatment quality and costs in usual care practice. Psychopharmacology Bulletin, 2008, 41, 24-39.	0.0	5
67	Impact of Full Mental Health and Substance Abuse Parity for Children in the Federal Employees Health Benefits Program. Pediatrics, 2007, 119, e452-e459.	2.1	36
68	Changes in the Quality of Care for Bipolar I Disorder During the 1990s. Psychiatric Services, 2007, 58, 27-33.	2.0	30
69	Quality of Care in a Medicaid Population With Bipolar I Disorder. Psychiatric Services, 2007, 58, 848-854.	2.0	26
70	Patients' Perception of Possible Child Custody or Visitation Loss for Nonadherence to Psychiatric Treatment. Psychiatric Services, 2007, 58, 999-1002.	2.0	20
71	The Impact of Parity on Major Depression Treatment Quality in the Federal Employees' Health Benefits Program After Parity Implementation. Medical Care, 2006, 44, 506-512.	2.4	34
72	Schizophrenia, Co-occurring Substance use Disorders and Quality of Care: The Differential Effect of a Managed Behavioral Health Care Carve-out. Administration and Policy in Mental Health and Mental Health Services Research, 2006, 33, 388-397.	2.1	10

#	Article	lF	CITATION
73	Behavioral Health Insurance Parity for Federal Employees. New England Journal of Medicine, 2006, 354, 1378-1386.	27.0	199
74	Introduction. Harvard Review of Psychiatry, 2006, 14, 183-184.	2.1	1
75	Quality-constant "prices―for the ongoing treatment of schizophrenia: an exploratory study. Quarterly Review of Economics and Finance, 2004, 44, 390-409.	2.7	17
76	The Effect of a Managed Behavioral Health Carve-Out on Quality of Carefor Medicaid Patients Diagnosed as Having Schizophrenia. Archives of General Psychiatry, 2004, 61, 442.	12.3	62